See the DrugPatentWatch profile for cosentyx

There is currently no definitive data on how the COVID-19 vaccine impacts the efficacy of Cosentyx (secukinumab). Cosentyx is a medication used to treat several types of autoimmune disorders, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

The U.S. Food and Drug Administration (FDA) has approved Cosentyx, and it works by blocking a specific protein (interleukin-17A) that can cause inflammation and lead to symptoms of these conditions [2].

On the other hand, COVID-19 vaccines (Pfizer-BioNTech, Moderna, Johnson & Johnson/Janssen) have been authorized for emergency use in the United States to prevent coronavirus disease 2019 (COVID-19) [3]. These vaccines work by teaching our immune systems how to recognize and fight the virus that causes COVID-19 [3].

Since both Cosentyx and COVID-19 vaccines have different mechanisms of action, it is uncertain how one would impact the other. However, the Centers for Disease Control and Prevention (CDC) recommends that people with autoimmune conditions, including those on immunosuppressive therapies, receive a COVID-19 vaccine [4]. The CDC also mentions that the potential benefits of getting a COVID-19 vaccine are likely to outweigh the potential risks for most people [4].

It is essential to consult healthcare professionals for personalized advice regarding the COVID-19 vaccine and its potential impact on Cosentyx treatment [5]. They can provide the most accurate and up-to-date information based on the individual's medical history and current health status.

In summary, there is no conclusive data on how the COVID-19 vaccine impacts Cosentyx's efficacy. However, the CDC recommends that people with autoimmune conditions receive a COVID-19 vaccine, considering the benefits outweigh the risks. Consult healthcare professionals for personalized advice.

Sources:
[1] Cosentyx (secukinumab) injection, for subcutaneous use [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. Retrieved from https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf
[2] U.S. Food and Drug Administration. (2021). Cosentyx. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cosentyx-secukinumab
[3] Centers for Disease Control and Prevention. (2021). COVID-19 Vaccines. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html
[4] Centers for Disease Control and Prevention. (2021). People with Certain Medical Conditions. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
[5] DrugPatentWatch. (2021). Cosentyx (secukinumab). Retrieved from https://www.drugpatentwatch.com/drugs/cosentyx